Full Text View
Tabular View
Study Results
Related Studies
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
This study has been completed.
Study NCT00110357   Information provided by Bristol-Myers Squibb
First Received: May 6, 2005   Last Updated: August 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Refractory Solid Tumor
Interventions listed in this trial
Cetuximab + Irinotecan
Cetuximab + Irinotecan
Additional drug interventions recognized in this trial
Cetuximab
Irinotecan
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Bristol-Myers Squibb
ImClone LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services